Promising Penny Stocks To Consider In December 2024

In This Article:

As global markets continue to reach record highs, with indices such as the Dow Jones and S&P 500 marking significant gains, investors are on the lookout for opportunities that align with current economic conditions. Penny stocks, a term often associated with smaller or newer companies, still hold potential for growth when these entities demonstrate strong financial health. In this article, we will explore three penny stocks that stand out due to their robust balance sheets and potential for long-term success.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

DXN Holdings Bhd (KLSE:DXN)

MYR0.48

MYR2.39B

★★★★★★

Embark Early Education (ASX:EVO)

A$0.79

A$144.95M

★★★★☆☆

Datasonic Group Berhad (KLSE:DSONIC)

MYR0.395

MYR1.1B

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.89

MYR295.43M

★★★★★★

ME Group International (LSE:MEGP)

£2.245

£845.83M

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$4.13

HK$45.48B

★★★★★★

LaserBond (ASX:LBL)

A$0.565

A$66.23M

★★★★★★

Lever Style (SEHK:1346)

HK$0.86

HK$545.92M

★★★★★★

Next 15 Group (AIM:NFG)

£4.335

£431.14M

★★★★☆☆

Secure Trust Bank (LSE:STB)

£3.57

£68.08M

★★★★☆☆

Click here to see the full list of 5,688 stocks from our Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

SSY Group

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: SSY Group Limited is an investment holding company that engages in the research, development, manufacturing, trading, and sale of various pharmaceutical products to hospitals and distributors both in the People's Republic of China and internationally, with a market cap of approximately HK$10.62 billion.

Operations: The company generates revenue from its Medical Materials segment, which contributes HK$402.49 million, and its Intravenous Infusion Solution and Others segment, which accounts for HK$6.30 billion.

Market Cap: HK$10.62B

SSY Group Limited has demonstrated stable earnings growth, with a 14.6% increase over the past year, surpassing both its five-year average and industry benchmarks. The company's financial health appears robust, with short-term assets exceeding liabilities and debt well covered by operating cash flow. Recent approvals from China's National Medical Products Administration for various drug products could enhance its market position. However, the dividend coverage is weak despite a low price-to-earnings ratio suggesting good value relative to peers. While the board is experienced, there is insufficient data on management tenure to assess leadership stability comprehensively.